PPI Lawsuit Settlement 2026: the NJ Master Settlement, the $425M Deal & Why 11,404 Cases Are Still Open

In late 2025, the New Jersey state-court proton pump inhibitor litigation — the quiet twin of the federal MDL 2789 — entered a Master Settlement Agreement with the AstraZeneca and Merck defendants, without any admission of fault. That agreement joins AstraZeneca's October 2023 $425 million settlement and Takeda's finalized November 2024 deal. Yet Judicial Panel on Multidistrict Litigation statistics show 11,404 PPI cases still active in October 2026. Here is what has actually settled, what has not, and who can still file.

Following a decade-long pharmaceutical litigation across two court systems takes patience. The Problem Solved channel explains major mass-tort developments in plain English — a useful companion as settlements like these keep arriving.

Key facts

  • MDL 2789 — the federal PPI litigation, centralized in 2017 before Judge Claire C. Cecchi in the District of New Jersey — is one of the largest pharmaceutical dockets in the country: 18,755 people have filed PPI kidney-injury lawsuits, with 11,404 still active as of October 2026 (JPML statistics).
  • In October 2023, AstraZeneca announced a $425 million settlement covering claims against Nexium and Prilosec, days before the October 10, 2023 bellwether trial; its 2025 annual report says those claims were resolved 2022–2024, with only a small number of opt-outs.
  • Takeda (Prevacid, Dexilant) reached an agreement in principle in April 2024, with a final settlement executed in November 2024 — company-specific, not part of the AstraZeneca deal.
  • The New Jersey state-court consolidated litigation (ATL-L-1259-20) — about 50 cases at its height against the AstraZeneca and Merck defendants — entered a Master Settlement Agreement without admission of fault, recorded in Case Management Order No. 7 filed November 14, 2025.
  • The claimed injuries are acute interstitial nephritis, chronic kidney disease, acute kidney injury, and kidney failure — supported by research including JAMA Internal Medicine (2016) and the Journal of the American Society of Nephrology (2016).

The two tracks you need to understand

A proton pump inhibitor (PPI) is a drug that reduces stomach-acid production; the class includes Nexium, Prilosec, Prevacid, Protonix, Dexilant, Zegerid, AcipHex, and Vimovo. The litigation runs on two parallel tracks, and confusing them is the easiest way to misread the headlines.

The first is the federal multidistrict litigation: MDL 2789 before Judge Cecchi. An MDL consolidates thousands of individual federal lawsuits for pretrial handling while keeping each plaintiff's case separate. The second is the New Jersey state-court consolidated litigation — far fewer cases, proceeding under state rules on its own settlement timeline. The November 2025 Master Settlement belongs to that state-court track, not the federal MDL. Settlements in one track do not automatically resolve cases in the other.

What the settlements actually cover

Every documented resolution so far is company-specific — there has never been one global settlement covering all PPI makers. AstraZeneca's $425 million deal resolved the bulk of claims against Nexium (esomeprazole) and Prilosec (omeprazole). Takeda's settlement, agreed in April 2024 and finalized in November 2024, covers Prevacid (lansoprazole) and Dexilant (dexlansoprazole).

The November 2025 New Jersey Master Settlement covers the state-court cases against the AstraZeneca and Merck defendants — entered, in the court's words, "without admission of fault or liability." A master settlement agreement is a framework deal setting the terms under which batches of individual cases resolve, not a single check to a class. The details that matter most — eligibility, claim valuation, deadlines — live in the settlement's claims process, which is why attorneys urge people with potential claims to get evaluated rather than assume they are covered.

The science the claims rest on

The core allegation is failure to warn: that manufacturers knew, or should have known, of serious kidney risks from long-term PPI use and did not adequately warn patients or doctors. The research foundation includes two landmark 2016 studies — Lazarus and colleagues in JAMA Internal Medicine, linking PPI use to chronic kidney disease, and Xie and colleagues in the Journal of the American Society of Nephrology, linking PPIs to incident CKD and progression to end-stage renal disease. The FDA's own safety communications flagged bone-fracture risk (2010, updated 2011), low magnesium (2011), and C. difficile infection (2012) — a paper trail plaintiffs use to argue the companies were on notice.

The injuries form a ladder of severity: acute interstitial nephritis (sudden kidney inflammation), acute kidney injury, chronic kidney disease (gradual function loss), and kidney failure requiring dialysis or transplant. Proving a case typically requires pharmacy records documenting PPI use, medical records showing kidney-function decline during or after that use, and expert testimony ruling out alternatives such as diabetes, hypertension, or other kidney-toxic drugs. A few representative cases are tried first as bellwethers to test both sides' arguments — and those tests shaped much of the settlement negotiating.

Why 11,404 cases are still open

If three settlements have been announced, why are 11,404 cases still active? Because in mass torts, "settlement" is plural. First, the opt-outs: a small but real number of plaintiffs declined the AstraZeneca deal and kept their cases alive. Second, coverage gaps: each deal binds only its own defendant, so claims against other manufacturers proceed on their own schedules. Third, the long tail: new qualifying cases keep being evaluated and filed, and confidential individual settlements take time to wind through the system.

The litigation is substantially resolved for the biggest defendants while remaining very much alive at the margins — exactly where late filers tend to live. The Valsartan NDMA settlement is a close parallel: the headline number covered only part of the story while individual claims continued on separate tracks.

Who can still file — and what you will need

You may still have a viable claim if you took a prescription PPI long-term and later developed kidney problems — acute interstitial nephritis, CKD, acute kidney injury, or kidney failure. The strongest files contain pharmacy or insurance records proving sustained use, medical records documenting kidney-function decline with timing that fits the exposure, and no obvious alternative explanation.

Three practical notes. First, statutes of limitations vary by state and often run one to three years; the discovery rule can delay the clock until you reasonably learned of the link, but do not rely on it — get evaluated promptly. Second, nearly all of these attorneys work on contingency: no upfront fees, payment only if you recover. Third, compensation varies widely by case, and most settlements are confidential — treat any source quoting a payout range as unreliable. The Topamax verdicts show how a few trial outcomes can reshape settlement talks for an entire litigation; for the broader picture, see our PPI lawsuit guide.

Who Benefits From This — and Who Does Not

This article is for people who took a proton pump inhibitor and later developed kidney problems, and for anyone trying to tell the settled PPI claims apart from the 11,404 cases still active in October 2026. The settlements described here are company-specific deals, not a single fund paying every claimant.

Who benefits:

  • People with a qualifying kidney injury after PPI use: The claimed injuries are acute interstitial nephritis, chronic kidney disease, acute kidney injury, and kidney failure, supported by research including JAMA Internal Medicine (2016).
  • People who used a named brand: AstraZeneca's October 2023 $425 million settlement covered Nexium and Prilosec claims, and Takeda's finalized November 2024 deal covered Prevacid and Dexilant; the late-2025 New Jersey Master Settlement Agreement covered the AstraZeneca and Merck defendants in the state-court litigation.
  • People whose cases are still open: With 11,404 PPI cases still active in October 2026, an open case may still be pursued rather than assumed settled.

Who does not benefit, or not much:

  • People who took a PPI without a qualifying kidney injury: A claim turns on a documented kidney injury, not on PPI use alone.
  • People whose claims were already resolved under the AstraZeneca deal: Its 2025 annual report says those Nexium and Prilosec claims were resolved, so they are not part of the still-open docket.
  • Anyone who assumes every PPI case has settled: The federal MDL 2789 and the state-court tracks moved separately, and thousands of cases remain open.

For the earlier PPI filing guide, see also: PPI Nexium Prilosec Lawsuit 2026: Kidney Injury Claims, File.

Frequently asked questions

Has the PPI litigation settled?

Partly. AstraZeneca settled Nexium and Prilosec claims in a $425 million deal announced in October 2023, Takeda finalized its settlement in November 2024, and the New Jersey state-court cases entered a Master Settlement Agreement in late 2025. But JPML statistics still show 11,404 active cases in October 2026.

What kidney injuries qualify for a PPI claim?

The claims allege acute interstitial nephritis, chronic kidney disease, acute kidney injury, and kidney failure after long-term PPI use. Each case turns on pharmacy records proving sustained use and medical records showing kidney-function decline tied to that use.

Which PPI brands are named in the lawsuits?

Nexium and Prilosec (AstraZeneca) and Prevacid and Dexilant (Takeda) have company-specific settlements; the New Jersey Master Settlement names the AstraZeneca and Merck defendants. Protonix, Zegerid, AcipHex, and Vimovo also appear in filings.

Is it too late to file a PPI lawsuit?

Not necessarily. Statutes of limitations differ by state, and the discovery rule can delay the clock until you reasonably learned of the link between PPIs and your kidney injury. Because these rules vary, talk to an attorney promptly rather than assuming the window has closed.

Who benefits most from this PPI settlement guide?

People with a documented qualifying kidney injury — acute interstitial nephritis, chronic kidney disease, acute kidney injury, or kidney failure — after using a named PPI brand such as Nexium, Prilosec, Prevacid, or Dexilant, and whose cases are among the 11,404 still active in October 2026.

How do I start if I think I have a PPI kidney claim?

Confirm which PPI brand you took and gather medical records showing a qualifying kidney injury and its timing, then have a qualified attorney check whether your claim falls under a resolved deal — such as AstraZeneca's $425 million Nexium and Prilosec settlement — or remains among the still-open cases.

Disclaimer: this article is general information, not legal or medical advice. PPI claims turn on individual medical facts, and only a qualified attorney can evaluate your situation.

Watch on YouTube

Problem Solved on YouTube